-
EAU 25 | Professors Samson Chan and Junlong Zhuang : PARPi Treatment Shows Initial Efficacy in mHSPC, Advancing Precision Therapy for Prostate Cancer
PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II…
-
Prof. Benlong Yang Named First Chinese Scholar to Receive “Youth Education Ambassador” and “Social Media Ambassador” Titles at SGBCC
The 19th St. Gallen Breast Cancer Conference (SGBCC) took place in Vienna, Austria, from March 12 to 15, 2025. As one of the most prestigious biennial academic events in breast cancer research, SGBCC gathers leading global experts to discuss evolving treatment strategies for early breast cancer, voting on recommendations that shape clinical practice. Notably, this…
-
SGBCC Voice of China | Prof. Qiang Liu: Viewing Early Breast Cancer as a Systemic Disease from a ctDNA Perspective
Oncology Frontier: At this year’s SGBCC “Voice of China” session, you presented a report on dynamic ctDNA monitoring for stratifying relapse risk and guiding precision treatment in early TNBC. Could…
-
Final TUXEDO-1 Trial Results: Trastuzumab Deruxtecan in HER2+ Breast Cancer with Active Brain Metastases
Published in Neuro-Oncology on July 4, 2024, the final analysis from the phase II TUXEDO-1 trial confirms the strong intracranial and systemic efficacy of trastuzumab deruxtecan (T-DXd) in patients with…
-
Is Fecal Immunochemical Testing the Right FIT for Patients With Symptoms?
In their recent Gastroenterology editorial, Dr. Audrey H. Calderwood (Dartmouth-Hitchcock Medical Center) and Dr. Theodore R. Levin (Kaiser Permanente) raise a compelling question: can fecal immunochemical testing (FIT) be used beyond colorectal cancer (CRC) screening — to guide colonoscopy decisions in patients with GI symptoms?
-
Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe
Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes. In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the…
-
Dr. Kefeng Ding: Exploration of the Balance between Radical Resection and Functional Preservation in Colorectal Cancer Treatment with LISH Procedure| Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee
At the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Kefeng Ding from The Second Affiliated Hospital Zhejiang University School of Medicine presented innovative advancements in laparoscopic ileocecal-sparing hemicolectomy (LISH) for right-sided colon cancer, highlighting its potential to balance oncologic radicality with functional preservation. His insights provide valuable guidance for…
-
Dr. Xiujuan Qu: Breakthroughs in Precision Treatment for Advanced Colorectal Cancer – KRAS G12C Inhibitors Leading the Way
With the discovery of molecular targets and the development of corresponding targeted inhibitors, the treatment of metastatic colorectal cancer (mCRC) is becoming increasingly precise and personalized. At the recent 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Xiujuan Qu from The First Hospital of China Medical University shared the latest…
Connecting Medical Expertise through Media